arrow
Y

Yongxian Hu

zhejiang university
H指数:30
被引数:3,380

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Pre-Transplant MRD Negativity and Age Under 40 Predict Superior Long-Term Survival in Relapsed/Refractory B-ALL After CAR-T Therapy Bridging to Haploidentical HSCT: A Multicenter Retrospective Study With 6-Year Follow-Up

移植前微小残留病阴性及年龄小于40岁预测CAR-T治疗后复发/难治性B-ALL行半相合造血干细胞移植桥接治疗患者的长期生存优势:一项随访6年的多中心回顾性研究

2026-05-130
PRE
Predictive values of baseline 18F-FDG PET/CT for toxicities and outcomes in patients with relapsed or refractory multiple myeloma following BCMA CAR T-cell therapy

基线18F-FDG PET/CT对BCMA CAR T细胞治疗后复发或难治性多发性骨髓瘤患者毒性和预后的预测价值

2025-12-130
PRE
Co-infusion of CD19-targeting and BCMA-targeting CAR-T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial

CD19靶向和BCMA靶向CAR-T细胞的联合输注治疗难治性系统性红斑狼疮:一项1期临床试验

2025-09-240
PRE
Safety and efficacy of autologous humanized CD19 CAR-T cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma

自体人源化CD19 CAR-T细胞疗法治疗复发/难治性B细胞非霍奇金淋巴瘤的安全性与有效性

2025-08-200
OAAI
Dasatinib and CAR T-Cell Therapy in Newly Diagnosed Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia: A Nonrandomized Clinical Trial

达沙替尼和CAR T细胞疗法在初诊费城染色体阳性急性淋巴细胞白血病中的应用:一项非随机临床试验

2025-04-170
PRE
Long-term follow-up of BCMA CAR-T cell therapy in patients with relapsed/refractory multiple myeloma

BCMA CAR-T细胞疗法在复发/难治性多发性骨髓瘤患者中的长期随访

2025-03-280
OA
Recommendations for the timing, dosage, and usage of corticosteroids during cytokine release syndrome (CRS) caused by chimeric antigen receptor (CAR)-T cell therapy for hematologic malignancies
2024-11-050
OAAI